Edition:
United Kingdom

Galapagos NV (GLPG.OQ)

GLPG.OQ on NASDAQ Stock Exchange Global Select Market

84.48USD
14 Dec 2017
Change (% chg)

$-1.15 (-1.34%)
Prev Close
$85.63
Open
$84.86
Day's High
$85.14
Day's Low
$84.15
Volume
58,866
Avg. Vol
40,290
52-wk High
$104.09
52-wk Low
$58.31

Latest Key Developments (Source: Significant Developments)

Galapagos NV reports Q3 loss of ‍1.75​ euro per share
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Galapagos NV -:Galapagos NV qtrly ‍revenues 106.4 million euro versus 65 million euro​.Galapagos NV qtrly loss per share ‍1.75​ euro.Galapagos NV says ‍we anticipate cash burn for full year to be at lower end of guidance of euro 135 million - 155 million​.  Full Article

Galapagos gets orphan drug designation in EU for GLPG1690 in idiopathic pulmonary fibrosis
Tuesday, 6 Sep 2016 

Galapagos NV :Orphan drug designation in European Union for GLPG1690 in idiopathic pulmonary fibrosis.  Full Article

Galapagos to be included in AEX index
Thursday, 9 Jun 2016 

Galapagos NV : Says selected for AEX index <.AEX> .Inclusion is effective June 20, 2016.  Full Article

Galapagos creates new warrant plan
Thursday, 2 Jun 2016 

Galapagos NV : Announced on Wednesday the creation of 865,000 warrants under new warrant plans . Warrants created under Warrant Plan 2016 and Warrant Plan 2016 RMV were offered on June 1, 2016 . Warrants have an exercise term of eight years as of the date of the offer and have an exercise price of 46.10 euros ($51.65) .Warrants as such will not be listed on any stock market.  Full Article

Galapagos says completed end-of-Phase 2 FDA and EMA consultations in rheumatoid arthritis
Tuesday, 24 May 2016 

Galapagos Nv : Successful completion of end-of-phase 2 FDA and EMA consultations in rheumatoid arthritis (RA) . Completion of discussions with regulatory authorities in US and Europe . Discloses doses for Finch global phase 3 program with filgotinib in RA . Finch program will investigate efficacy and safety of 100 mg and 200 mg filgotinib once-daily, with dosing expected to begin in Q3'16 . Finch phase 3 program will also contain a dedicated male patient testicular safety study .Gilead expects to initiate a phase 3 study with filgotinib in Crohn's disease and a phase 2/3 study in ulcerative colitis in Q3 '16.  Full Article

Galapagos listing of existing shares on Euronext Brussels & Amsterdam
Tuesday, 17 May 2016 

Galapagos NV :6,760,701 shares subscribed to by Gilead on 19 January have been admitted to trading on Euronext Brussels and Amsterdam.  Full Article

Galapagos to list 6,760,701 new shares - Euronext
Thursday, 12 May 2016 

Euronext: 6,760,701 new ordinary shares issued by Galapagos will be listed on Euronext Amsterdam as of May 17 following private placement . Reference price: 58 euros ($66.14) Further company coverage: [GLPG.AS] ($1 = 0.8770 euros) (Gdynia Newsroom:) ((Gdynia.newsroom@thomsonreuters.com; +48 58 698 39 20;)).  Full Article

Galapagos and Abbvie expand their cystic fibrosis collaboration
Friday, 29 Apr 2016 

Galapagos NV:Galapagos and Abbvie expand their cystic fibrosis collaboration.Companies have agreed to increase potential milestones to Galapagos for phase 1 and 2 achievements.Bringing remaining total milestones in CF alliance up to approximately $600 million, from $350 million.  Full Article

Galapagos confirms FY 2016 guidance
Thursday, 28 Apr 2016 

Galapagos NV:Guidance reiterated for 2016 cash burn of 100–120 million euros (excluding payments received from Gilead for filgotinib).  Full Article

Galapagos and Morphosys initiate phase 1 study in joint antibody program MOR106
Thursday, 7 Apr 2016 

Galapagos NV:Galapagos and Morphosys MORG.DE initiate phase 1 study in joint antibody program MOR106.Primary objective of phase 1 study is to evaluate safety and tolerability of single doses of MOR106.Topline results of complete study are expected in second half of 2017.  Full Article

BRIEF-Galapagos To Enter NASDAQ Biotech Index Effective Dec 18‍​

* TO ENTER NASDAQ BIOTECH INDEX EFFECTIVE DEC 18‍​ Source text: http://bit.ly/2jM5AGV Further company coverage: (Gdynia Newsroom)